Cancer@Work; a nurse-led web-based intervention to enhance the return-to-work of cancer survivors - a multi-center randomised controlled trial

Published: 16-06-2015
Last updated: 15-05-2024

To enhance sustainable return to work of cancer survivors of working age.

Ethical review	Approved WMO
Status	Recruitment stopped
Health condition type	Miscellaneous and site unspecified neoplasms benign
Study type	Interventional

Summary

ID

NL-OMON43598

Source
ToetsingOnline

Brief title
Cancer@Work

Condition

- Miscellaneous and site unspecified neoplasms benign

Synonym
Cancer

Research involving
Human

Sponsors and support

Primary sponsor: Academisch Medisch Centrum
Source(s) of monetary or material Support: Alpe D'HuZes / KWF

Intervention

Keyword: Cancer survivors, Cost-effectiveness, Return to work, Web-based intervention

Outcome measures

Primary outcome

Sustainable return to work measured as return to work (yes/no) which is sustained for at least four consecutive weeks. Return to work is regardless of partial return to work (working a part of contract hours) or full return to work (working all contract hours).

Secondary outcome

Full return to work (working all contract hours) for at least four consecutive weeks.

Time in days to return to work (yes/no) for at least four consecutive weeks. Return to work is regardless of partial return to work (working a part of contract hours) or full return to work (working all contract hours).

Time in days to full return to work (working all contract hours) for at least four consecutive weeks.

Work ability

Work limitations

Quality of life

Quality of work life

Return to work without extensive need for recovery

Cost-effectiveness of the web-based intervention Cancer@Work

Feasibility of the web-based intervention Cancer@Work

Intermediate effect of the intervention on self-management and work-related

self-efficacy.

Study description

Background summary

In the last decades, the survival rates of cancer have improved significantly for most cancer types. For that reason, a growing number of cancer survivors of working age is now able to remain in or return to work. However, a considerable number of cancer patients still experience difficulties getting back to work or becoming unemployed. It is important to diminish these adverse work outcomes for cancer patients, as work is a key aspect of cancer survivorship and as work is associated with higher levels of quality of life in cancer patients. To reduce these negative consequences for cancer patients as well as for the society at large, we developed an intervention to support return to work in cancer patients. The hypothesis is that the patients who receive the web-based intervention will have better work outcomes at 12 months of follow-up compared to patients who receive care as usual.

Study objective

To enhance sustainable return to work of cancer survivors of working age.

Study design

Multi-centre non-blinded randomised controlled trial.

Intervention

The intervention consists of access to the web-based intervention, Cancer@Work, which will be blended with care by their specialised nurse or social worker. Cancer@Work, is a interactive, personal website, aimed at enhancing the return to work of cancer survivors by means of tailor-made information, assignments and movies. Patients will be supported in their use of Cancer@Work by their specialised nurse or social worker of their treating hopsital.

Study burden and risks

There are no risks associated with participation. The web-based intervention is developed, build and will be hosted by the ICT department of the AMC.

Since the use of the web-based intervention is not prescribed in terms of length, frequency, and duration, the burden to participate is variable.

Patients themselves decide when to use the web-based intervention and which content. The web-based intervention will be available for 12 months. The burden to participate for all patients will be 4.30 hours for filling in 5 questionnaires spread during the 12 months of follow-up.

Contacts

Public
Academisch Medisch Centrum

Meibergdreef 9
Amsterdam 1105 AZ
NL
Scientific
Academisch Medisch Centrum

Meibergdreef 9
Amsterdam 1105 AZ
NL

Trial sites

Listed location countries

Netherlands

Eligibility criteria

Age
Adults (18-64 years)
Elderly (65 years and older)

Inclusion criteria

Primary diagnosis of cancer
Treated with curative intent at the hospital of recruitment
Between 18-62 years old
In paid employment or self-employed at cancer diagnosis

Exclusion criteria

Have a severe co-morbidity
Have no Internet access
Are not able to speak, read, and write Dutch sufficiently well
Receiving primary treatment in another hospital than hospital of recruitment.

Study design

Design

Study type:	Interventional
Intervention model:	Parallel
Allocation:	Randomized controlled trial
Masking:	Open (masking not used)

Primary purpose: Treatment

Recruitment

NL

Recruitment status:	Recruitment stopped
Start date (anticipated):	09-09-2015
Enrollment:	190
Type:	Actual

Ethics review

Approved WMO Date:	16-06-2015
Application type:	First submission
Review commission:	METC Amsterdam UMC
Approved WMO Date:	26-06-2015
Application type:	Amendment
Review commission:	METC Amsterdam UMC
Approved WMO	

Date:	26-08-2015
Application type:	Amendment
Review commission:	METC Amsterdam UMC
Approved WMO Date:	11-11-2015
Application type:	Amendment
Review commission:	METC Amsterdam UMC
Approved WMO Date:	23-12-2015
Application type:	Amendment
Review commission:	METC Amsterdam UMC
Approved WMO Date:	16-02-2016
Application type:	Amendment
Review commission:	METC Amsterdam UMC

Study registrations

Followed up by the following (possibly more current) registration

No registrations found.

Other (possibly less up-to-date) registrations in this register

ID: 24044
Source: NTR
Title:

In other registers

Register	ID
CCMO	NL51798.018.14
OMON	NL-OMON24044